Form 4 for PCVX Vaxcyte, Inc.

Accepted 2026-09-09 17:46:35 ET · period of report 2026-09-04 · accession 0001813798-26-000019 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2026-09-09 17:46	2026-09-04+	PCVX	Wassil Jim	EVP, COO, Chief Scientific Ofc	S - Sale	$60.35	-2,715	145.4K	-2%	-$163.9K
	2026-09-09 17:46	2026-09-08	PCVX	Wassil Jim	EVP, COO, Chief Scientific Ofc	F - Tax	$60.36	-5,459	146.8K	-4%	-$329.5K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-09-04	S	D	1,381	$61.16	152,228	D	—	—	(F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $60.95 to $61.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
2	Common	Common Stock	2026-09-08	F	D	5,459	$60.36	146,769	D	—	—	(F3) Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
3	Common	Common Stock	2026-09-09	S	D	1,334	$59.52	145,435	D	—	—	(F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F4) The price reported is a weighted-average price. The shares were sold at prices ranging from $59.155 to $60.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.